Colella R, Loiacono G, Bagnulo S, Demichele N, Diterlizzi M, Amendola F, Ceci A
Pediatr Med Chir. 1985 Jul-Aug;7(4):541-4.
38 children with Non-Hodgkin Lymphoma (age 15 months - 17 years; 27 males and 11 females) have been treated between 1974 and 1982. They have been divided in two different groups: a Good Prognosis group for patients with complete resectable disease and a Poor Prognosis group including patients with mediastinal, bone marrow or CNS involvement or with diffuse and non completely resectable localization. In the Good Prognosis group there were 100% Complete Remission, 12.5% Local Relapses and 12.5% deaths. 88% of patients are alive at 8 1/2 years follow-up. In the Poor Prognosis group there were 83% Complete Remission, 50% Relapses (8 in the first year, 2 in the second and 5 in the third and no more in the next years) and 60% Deaths; 30% of patients are off-therapy with a survival of 40% at 8 1/2 years follow-up. Among the 19 patients with mediastinal involvement there were 84.2% Complete Remission, 68.4% Relapses, 63.1% Deaths and 26.6% off therapy patients. Among the 19 patients with mediastinal involvement there were 84.2% Complete Remission, 68.4% Relapses, 63.1% Deaths and 26.6% off therapy patients. Survival is 70% for the group without mediastinal involvement and 35% for the group with mediastinal involvement. Burkitt-type Lymphoma has a survival of 30% in contrast to the 60% survival for all the others histological types. In summary we conclude that the distinction between Good Prognosis and Poor Prognosis groups, on the basis of a clinical stage involvement and Burkitt histology have an important role for prognosis of Non-Hodgkin Lymphoma in children.
1974年至1982年间，对38例非霍奇金淋巴瘤患儿（年龄15个月至17岁；男27例，女11例）进行了治疗。他们被分为两个不同的组：疾病可完全切除的预后良好组和包括纵隔、骨髓或中枢神经系统受累或病变弥漫且不可完全切除的预后不良组。预后良好组的完全缓解率为100%，局部复发率为12.5%，死亡率为12.5%。在8年半的随访中，88%的患者存活。预后不良组的完全缓解率为83%，复发率为50%（第一年8例，第二年2例，第三年5例，此后无复发），死亡率为60%；30%的患者停止治疗，在8年半的随访中生存率为40%。在19例纵隔受累患者中，完全缓解率为84.2%，复发率为68.4%，死亡率为63.1%，停止治疗的患者为26.6%。在19例纵隔受累患者中，完全缓解率为84.2%，复发率为68.4%，死亡率为63.1%，停止治疗的患者为26.6%。无纵隔受累组的生存率为70%，有纵隔受累组的生存率为35%。伯基特型淋巴瘤的生存率为30%，而其他所有组织学类型的生存率为60%。总之，我们得出结论，根据临床分期受累情况和伯基特组织学区分预后良好组和预后不良组，对儿童非霍奇金淋巴瘤的预后具有重要作用。
